Bridgewater Associates LP Cuts Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Bridgewater Associates LP lessened its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 28.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 21,836 shares of the medical device company's stock after selling 8,813 shares during the period. Bridgewater Associates LP's holdings in Cooper Companies were worth $2,007,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Cooper Companies in the 4th quarter valued at $691,000. Highland Capital Management LLC bought a new stake in shares of Cooper Companies in the fourth quarter worth about $4,004,000. Caprock Group LLC purchased a new stake in shares of Cooper Companies in the fourth quarter worth about $282,000. Franklin Resources Inc. boosted its stake in Cooper Companies by 194.0% during the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company's stock valued at $5,265,000 after buying an additional 32,260 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Cooper Companies by 6.6% during the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company's stock valued at $26,295,000 after buying an additional 14,687 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Up 1.3 %

Shares of COO traded up $1.07 during mid-day trading on Wednesday, reaching $80.86. 1,434,759 shares of the company's stock traded hands, compared to its average volume of 1,419,591. The Cooper Companies, Inc. has a 12 month low of $69.81 and a 12 month high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The stock has a market cap of $16.17 billion, a P/E ratio of 41.47, a P/E/G ratio of 2.25 and a beta of 1.01. The stock's 50-day moving average is $82.52 and its two-hundred day moving average is $93.20.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. Research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the topic of several recent research reports. Stifel Nicolaus decreased their price objective on Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Piper Sandler restated an "overweight" rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. BNP Paribas upgraded Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. Finally, Robert W. Baird decreased their price objective on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.